Standard Molecular

Cambridge, United States Founded: 2014 • Age: 12 yrs
Standard Molecular provides genomic information systems for diagnostic and therapeutic applications.
Annual revenue - Latest available
Total funding $1.4M 1 rounds
Employees - Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Standard Molecular

Standard Molecular is a company based in Cambridge (United States) founded in 2014 by Chesley Leslin, Nathaniel Weiss, and David Artz. It operates as a B2B. Standard Molecular has raised $1.44 million across 1 funding round. Standard Molecular operates in a competitive market with competitors including DNAnexus, Helix, Benchling, Cytel and Genuity Science, among others.

  • Headquarter Cambridge, United States
  • Founders Chesley Leslin, Nathaniel Weiss, David Artz
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Standard Molecular, Inc
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $1.44 M (USD)

    in 1 rounds

  • Latest Funding Round
    $1.44 M (USD), Seed

    Apr 09, 2018

  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Standard Molecular

Standard Molecular has successfully raised a total of $1.44M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.44 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investments & Acquisitions by Standard Molecular

Investments
Premium access

Investment portfolio details for Standard Molecular

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Standard Molecular

Premium access

Detailed financials for Standard Molecular

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Standard Molecular Comparisons

Standard Molecular Primary company
Description
Standard Molecular provides genomic information systems for ...
Location
Cambridge, United States
Founded Year
2014
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Standard Molecular

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Standard Molecular

Standard Molecular operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DNAnexus, Helix, Benchling, Cytel and Genuity Science, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Cloud-based genome informatics and data management are provided.
Locked Locked Locked
Genomic database for clinical research is provided.
Locked Locked Locked
Cloud-based bioinformatics platform is offered for biotech research.
Locked Locked Locked
Data analysis and statistical solutions are provided for life sciences.
Locked Locked Locked
AI-based omics data analysis solutions are provided to researchers.
Locked Locked Locked
Developer of predictive informatics based platform for drug discovery
Premium access

Detailed competitors of Standard Molecular

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Standard Molecular

Premium access

Complete news archive for Standard Molecular

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Standard Molecular

Standard Molecular was founded in 2014 and raised its 1st funding round 4 years after it was founded.

Standard Molecular is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Nathaniel Weiss is the current CEO of Standard Molecular. They have also founded this company.

Standard Molecular is a funded company, having raised a total of $1.44M across 1 funding round to date.

Standard Molecular, led by Chesley Leslin as Co-Founder, Nathaniel Weiss as ex-Founder, CEO, David Artz as Co-Founder, specializes in providing healthcare solutions, advancing biotech innovations, focusing on genomic solutions, and diagnostic systems. Standard Molecular provides genomic information systems for diagnostic and therapeutic applications. The team drives innovation, quality service, and sustainable practices to achieve excellence and client satisfaction.

Standard Molecular's top competitors include DNAnexus, Helix and Cytel.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available